Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 马碧如教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.2147/OTT.S48409 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/13WOS source URL
其它资讯
摘要Colorectal cancer is the second most common cancer in Hong Kong and its incidence is rising in economically developed Chinese cities, including Hong Kong and Shanghai. Several studies conducted in the People's Republic of China have characterized the unique molecular epidemiology of familial colorectal cancer syndromes and molecular biomarkers such as microsatellite instability and genetic mutations (eg, KRAS, NRAS, BRAF, PIK3CA, ERCC1) in Chinese populations. Interethnic differences in anticancer drug response and toxicity have been well described in many cancers, and this review examined the literature with regard to the tolerance of Chinese patients to commonly used chemotherapeutic regimens and targeted therapies for metastatic colorectal cancer. Studies on the pharmacogenomic differences in drug metabolizing and DNA repair enzymes between Chinese, North Asians, and Caucasian patients were also reviewed.
着者Li L, Ma BBY
期刊名称ONCOTARGETS AND THERAPY
出版年份2014
月份1
日期1
卷号7
出版社DOVE MEDICAL PRESS LTD
页次1817 - 1828
国际标準期刊号1178-6930
语言英式英语
关键词Chinese; colorectal cancer; treatment
Web of Science 学科类别Biotechnology & Applied Microbiology; Oncology
